Design of a bifunctional fusion protein for ovarian cancer drug delivery: Single-chain anti-CA125 core-streptavidin fusion protein

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 65, Issue 3, 2007, Pages 398-405

  Wang, Welson Wen Shang ^a   Das, Dipankar ^a   McQuarrie, Stephen A ^a   Suresh, Mavanur R ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Bifunctional fusion protein; Ovarian cancer; Recombinant antibody; Universal delivery vector and liposome

Indexed keywords

BIOTIN; BOVINE SERUM ALBUMIN; CA 125 ANTIGEN; HYBRID PROTEIN; LIPOSOME; RECOMBINANT DNA; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; STREPTAVIDIN;

AFFINITY CHROMATOGRAPHY; ARTICLE; BIOTINYLATION; CANCER CELL CULTURE; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; CULTURE TECHNIQUE; DRUG DELIVERY SYSTEM; DRUG SPECIFICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; EXTRACTION; GENE EXPRESSION SYSTEM; HUMAN; HUMAN CELL; OVARY CANCER; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; SHAKER FLASK CULTURE;

ANIMALS; ANTIBODY SPECIFICITY; ANTINEOPLASTIC AGENTS; BINDING SITES; BIOTIN; BLOTTING, WESTERN; CELL LINE, TUMOR; CLONING, MOLECULAR; DRUG CARRIERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOGLOBULIN VARIABLE REGION; MICE; MICROSCOPY, CONFOCAL; OVARIAN NEOPLASMS; PROTEINS; RECOMBINANT FUSION PROTEINS; STREPTAVIDIN;

EID: 33847309602     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2006.12.012     Document Type: Article

References (35)

1. Fernandez N., Duffour M.T., Perricaudet M., Lotze M.T., Tursz T., and Zitvogel L. Active specific T-cell-based immunotherapy for cancer: nucleic acids, peptides, whole native proteins, recombinant viruses, with dendritic cell adjuvants or whole tumor cell-based vaccines. Principles and future prospects. Cytokines Cell. Mol. Ther. 4 (1998) 53-65
2. Tighe H., Corr M., Roman M., and Raz E. Gene vaccination: plasmid DNA is more than just a blueprint. Immunol. Today 19 (1998) 89-97
3. Chatterjee M.B., Foon K.A., and Kohler H. Idiotypic antibody immunotherapy of cancer. Cancer Immunol. Immunother. 38 (1994) 75-82
4. Mobus V.J., Baum R.P., Bolle M., Kreienberg R., Noujaim A.A., Schultes B.C., and Nicodemus C.F. Immune responses to murine monoclonal antibody-B43.13 correlate with prolonged survival of women with recurrent ovarian cancer. Am. J. Obstet. Gynecol. 189 (2003) 28-36
5. Xiao Z., McQuarrie S.A., Suresh M.R., Mercer J.R., Gupta S., and Miller G.G. A three-step strategy for targeting drug carriers to human ovarian carcinoma cells in vitro. J. Biotechnol. 94 (2002) 171-184
6. Cannon M.J., Santin A.D., and O'Brien T.J. Immunological treatment of ovarian cancer. Curr. Opin. Obstet. Gynecol. 16 (2004) 87-92
7. Ehlen T.G., Hoskins P.J., Miller D., Whiteside T.L., Nicodemus C.F., Schultes B.C., and Swenerton K.D. A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer. Int. J. Gynecol. Cancer 15 (2005) 1023-1034
8. Kriangkum J., Xu B., Gervais C., Paquette D., Jacobs F.A., Martin L., and Suresh M.R. Development and characterization of a bispecific single-chain antibody directed against T cells and ovarian carcinoma. Hybridoma 19 (2000) 33-41
9. Wang W.W., Das D., and Suresh M.R. Biotin carboxyl carrier protein co-purifies as a contaminant in core-streptavidin preparations. Mol. Biotechnol. 31 (2005) 29-40
10. Kipriyanov S.M., Little M., Kropshofer H., Breitling F., Gotter S., and Dubel S. Affinity enhancement of a recombinant antibody: formation of complexes with multiple valency by a single-chain Fv fragment-core streptavidin fusion. Protein Eng. 9 (1996) 203-211
11. Dubel S., Breitling F., Kontermann R., Schmidt T., Skerra A., and Little M. Bifunctional and multimeric complexes of streptavidin fused to single chain antibodies (scFv). J. Immunol. Methods 178 (1995) 201-209
12. Kipriyanov S.M., Breitling F., Little M., and Dubel S. Single-chain antibody streptavidin fusions: tetrameric bifunctional scFv-complexes with biotin binding activity and enhanced affinity to antigen. Hum. Antibod. Hybridomas 6 (1995) 93-101
13. Schultz J., Lin Y., Sanderson J., Zuo Y., Stone D., Mallett R., Wilbert S., and Axworthy D. A tetravalent single-chain antibody-streptavidin fusion protein for pretargeted lymphoma therapy. Cancer Res. 60 (2000) 6663-6669
14. Markman M. Intraperitoneal therapy of ovarian cancer. Semin. Oncol. 25 (1998) 356-360
15. Wagner U., Kohler S., Reinartz S., Giffels P., Huober J., Renke K., Schlebusch H., Biersack H.J., Mobus V., Kreienberg R., Bauknecht T., Krebs D., and Wallwiener D. Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: immune responses and survival in palliative treatment. Clin. Cancer Res. 7 (2001) 1154-1162
16. Baum R.P., Noujaim A.A., Nanci A., Moebus V., Hertel A., Niesen A., Donnerstag B., Sykes T., Boniface G., and Hor G. Clinical course of ovarian cancer patients under repeated stimulation of HAMA using MAb OC125 and B43.13. Hybridoma 12 (1993) 583-589
17. Baum R.P., Niesen A., Hertel A., Nancy A., Hess H., Donnerstag B., Sykes T.R., Sykes C.J., Suresh M.R., Noujaim A.A., et al. Activating anti-idiotypic human anti-mouse antibodies for immunotherapy of ovarian carcinoma. Cancer 73 (1994) 1121-1125
18. Gabizon A. Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes. Cancer Res. 52 (1992) 891-896
19. Ahmad I., and Allen T.M. Antibody-mediated specific binding and cytotoxicity of liposome-entrapped doxorubicin to lung cancer cells in vitro. Cancer Res. 52 (1992) 4817-4820
20. Ahmad I., Longenecker M., Samuel J., and Allen T.M. Antibody-targeted delivery of doxorubicin entrapped in sterically stabilized liposomes can eradicate lung cancer in mice. Cancer Res. 53 (1993) 1484-1488
21. Zhang M., Zhang Z., Garmestani K., Schultz J., Axworthy D.B., Goldman C.K., Brechbiel M.W., Carrasquillo J.A., and Waldmann T.A. Pretarget radiotherapy with an anti-CD25 antibody-streptavidin fusion protein was effective in therapy of leukemia/lymphoma xenografts. Proc. Natl. Acad. Sci. USA 100 (2003) 1891-1895
22. Yao Z., Zhang M., Axworthy D.B., Wong K.J., Garmestani K., Park L., Park C.W., Mallett R.W., Theodore L.J., Yau E.K., Waldmann T.A., Brechbiel M.W., Paik C.H., Pastan I., and Carrasquillo J.A. Radioimmunotherapy of A431 xenografted mice with pretargeted B3 antibody-streptavidin and (90)Y-labeled 1,4,7,10-tetraazacyclododecane-N,N′,N″,N‴-tetraacetic acid (DOTA)-biotin. Cancer Res. 62 (2002) 5755-5760
23. Graves S.S., Dearstyne E., Lin Y., Zuo Y., Sanderson J., Schultz J., Pantalias A., Gray D., Axworthy D., Jones H.M., and Auditore-Hargreaves K. Combination therapy with pretarget CC49 radioimmunotherapy and gemcitabine prolongs tumor doubling time in a murine xenograft model of colon cancer more effectively than either monotherapy. Clin. Cancer Res. 9 (2003) 3712-3721
24. Knox S.J., Goris M.L., Tempero M., Weiden P.L., Gentner L., Breitz H., Adams G.P., Axworthy D., Gaffigan S., Bryan K., Fisher D.R., Colcher D., Horak I.D., and Weiner L.M. Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer. Clin. Cancer Res. 6 (2000) 406-414
25. Pavlinkova G., Batra S.K., Colcher D., Booth B.J., and Baranowska-Kortylewicz J. Constructs of biotin mimetic peptide with CC49 single-chain Fv designed for tumor pretargeting. Peptides 24 (2003) 353-362
26. Breitz H.B., Weiden P.L., Beaumier P.L., Axworthy D.B., Seiler C., Su F.M., Graves S., Bryan K., and Reno J.M. Clinical optimization of pretargeted radioimmunotherapy with antibody-streptavidin conjugate and 90Y-DOTA-biotin. J. Nucl. Med. 41 (2000) 131-140
27. Shen S., Forero A., LoBuglio A.F., Breitz H., Khazaeli M.B., Fisher D.R., Wang W., and Meredith R.F. Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies. J. Nucl. Med. 46 (2005) 642-651
28. Yao Z., Zhang M., Garmestani K., Axworthy D.B., Mallett R.W., Fritzberg A.R., Theodore L.J., Plascjak P.S., Eckelman W.C., Waldmann T.A., Pastan I., Paik C.H., Brechbiel M.W., and Carrasquillo J.A. Pretargeted alpha emitting radioimmunotherapy using (213)Bi 1,4,7,10-tetraazacyclododecane-N,N′,N″,N‴-tetraacetic acid-biotin. Clin. Cancer Res. 10 (2004) 3137-3146
29. Forster G.J., Santos E.B., Smith-Jones P.M., Zanzonico P., and Larson S.M. Pretargeted radioimmunotherapy with a single-chain antibody/streptavidin construct and radiolabeled DOTA-biotin: strategies for reduction of the renal dose. J. Nucl. Med. 47 (2006) 140-149
30. Nustad K., Onsrud M., Jansson B., and Warren D. CA 125-epitopes and molecular size. Int. J. Biol. Markers 13 (1998) 196-199
31. McQuarrie S., Mercer J., Syme A., Suresh M., and Miller G. Preliminary results of nanopharmaceuticals used in the radioimmunotherapy of ovarian cancer. J. Pharm. Pharm. Sci. 7 (2005) 29-34
32. Prokopenko P.G., Borisenko S.A., Sokolov A.V., and Terentyev A.A. Identification and characterization of serum protein in patients with ovarian cancer. Bull. Exp. Biol. Med. 133 (2002) 156-159
33. Cao Y., and Suresh M.R. Bispecific MAb aided liposomal drug delivery. J. Drug Target. 8 (2000) 257-266
34. L.J. Theodore, J.M. Reno, L.M. Gustavson, Three-step pretargeting methods and compounds, U.S. Patent 6,358,490, 2002.
35. O'Brien T.J., Beard J.B., Underwood L.J., Dennis R.A., Santin A.D., and York L. The CA 125 gene: an extracellular superstructure dominated by repeat sequences. Tumour Biol. 23 (2002) 154-169